Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma

[1]  K. Sigel,et al.  Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy , 2023, JAMA network open.

[2]  Victor G. Puelles,et al.  Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer , 2023, Nature.

[3]  S. Wong,et al.  Altered gut microbiome composition by appendectomy contributes to colorectal cancer , 2022, Oncogene.

[4]  G. Wang,et al.  Intratumoral bacteria are an important "accomplice" in tumor development and metastasis. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[5]  Shang Cai,et al.  Emerging roles of intratumor microbiota in cancer metastasis. , 2022, Trends in cell biology.

[6]  D. Ward,et al.  Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells , 2022, bioRxiv.

[7]  Donnele Daley.  The Role of the Microbiome in Pancreatic Oncogenesis. , 2022, International immunology.

[8]  L. Hall,et al.  Microbiome-based interventions to modulate gut ecology and the immune system , 2022, Mucosal Immunology.

[9]  Jinyan Liu,et al.  Intratumor microbiome in cancer progression: current developments, challenges and future trends , 2022, Biomarker research.

[10]  P. Bork,et al.  Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study. , 2022, Gastroenterology.

[11]  Wasiu A. Akanni,et al.  A faecal microbiota signature with high specificity for pancreatic cancer , 2022, Gut.

[12]  E. Giovannetti,et al.  A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma , 2022, Cancers.

[13]  James M. McFarland,et al.  Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer , 2021, Cell.

[14]  Xiangyin Kong,et al.  Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer , 2021, Communications biology.

[15]  M. Lotze,et al.  Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients , 2021, Cancer medicine.

[16]  L. McGeeney,et al.  Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines , 2021, BMJ open gastroenterology.

[17]  P. O’Toole,et al.  Dietary Fibre Modulates the Gut Microbiota , 2021, Nutrients.

[18]  U. Dobrindt,et al.  Gut microbiome as a response marker for pancreatic enzyme replacement therapy in a porcine model of exocrine pancreas insufficiency , 2020, Microbial Cell Factories.

[19]  J. Dahlerup,et al.  Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis , 2020, EClinicalMedicine.

[20]  N. Sakamoto,et al.  Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer , 2020, Medicine.

[21]  O. Pedersen,et al.  Gut microbiota in human metabolic health and disease , 2020, Nature Reviews Microbiology.

[22]  H. Völzke,et al.  The Gut Microbiome in Patients With Chronic Pancreatitis Is Characterized by Significant Dysbiosis and Overgrowth by Opportunistic Pathogens , 2020, Clinical and translational gastroenterology.

[23]  C. Pilarsky,et al.  Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development , 2020, Journal of Clinical Medicine.

[24]  G. Ianiro,et al.  The gut microbiome: what every gastroenterologist needs to know , 2020, Frontline Gastroenterology.

[25]  J. Vauthey,et al.  Surgical approach to synchronous colorectal liver metastases: staged, combined, or reverse strategy. , 2020, Hepatobiliary surgery and nutrition.

[26]  D. Ishikawa,et al.  DOP04 Matching between donors and patients in faecal microbiota transplantation is important for long-term maintenance on ulcerative colitis , 2020 .

[27]  C. Jobin,et al.  Microbiota in pancreatic health and disease: the next frontier in microbiome research , 2019, Nature Reviews Gastroenterology & Hepatology.

[28]  E. Daglilar,et al.  The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. , 2019, Current opinion in pharmacology.

[29]  Hang Xiao,et al.  Dietary Fibers from Fruits and Vegetables and Their Health Benefits via Modulation of Gut Microbiota. , 2019, Comprehensive reviews in food science and food safety.

[30]  Christine B. Peterson,et al.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes , 2019, Cell.

[31]  J. Allard,et al.  The role of the gut microbiome in chronic liver disease: the clinical evidence revised , 2019, JHEP reports.

[32]  H. Völzke,et al.  Impaired Exocrine Pancreatic Function Associates With Changes in Intestinal Microbiota Composition and Diversity. , 2019, Gastroenterology.

[33]  M. Strother,et al.  The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study , 2019, Palliative care.

[34]  Animesh Acharjee,et al.  The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease , 2019, Therapeutic advances in gastroenterology.

[35]  M. Lerch,et al.  Psychometric evaluation of a patient-reported outcome measure in pancreatic exocrine insufficiency (PEI). , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[36]  Sabita Roy,et al.  Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. , 2018, Gastroenterology.

[37]  A. Fodor,et al.  Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models , 2018, Carcinogenesis.

[38]  A. Ozet,et al.  Managing Synchronous Liver Metastases in Colorectal Cancer , 2018, Indian Journal of Surgical Oncology.

[39]  S. Pushalkar,et al.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. , 2018, Cancer discovery.

[40]  Inge A Lindseth,et al.  The Western Diet–Microbiome-Host Interaction and Its Role in Metabolic Disease , 2018, Nutrients.

[41]  R. Moffitt,et al.  Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial , 2017, Clinical Cancer Research.

[42]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[43]  W. Petritsch,et al.  The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.

[44]  J. Hodson,et al.  Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[45]  Noam Shental,et al.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine , 2017, Science.

[46]  A. Sainsbury,et al.  Strategies to Improve Adherence to Dietary Weight Loss Interventions in Research and Real-World Settings , 2017, Behavioral sciences.

[47]  C. Hill,et al.  Next-generation probiotics: the spectrum from probiotics to live biotherapeutics , 2017, Nature Microbiology.

[48]  M. Lerch,et al.  Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument , 2017, The Patient - Patient-Centered Outcomes Research.

[49]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[50]  J. Izbicki,et al.  Pancreatic cancer and liver metastases: state of the art , 2016, Updates in Surgery.

[51]  H. Tilg,et al.  Gut microbiome and liver diseases , 2016, Gut.

[52]  A. Khoruts,et al.  Understanding the mechanisms of faecal microbiota transplantation , 2016, Nature Reviews Gastroenterology &Hepatology.

[53]  D. Aust,et al.  Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection , 2016, Annals of Surgical Oncology.

[54]  Oluf Pedersen,et al.  Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials , 2016, Genome Medicine.

[55]  I. B. Borel Rinkes,et al.  Pancreatic Exocrine Insufficiency in Patients With Pancreatic or Periampullary Cancer: A Systematic Review , 2016, Pancreas.

[56]  L. Påhlman,et al.  Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. , 2015, Cancer treatment reviews.

[57]  Jacques Ravel,et al.  The vocabulary of microbiome research: a proposal , 2015, Microbiome.

[58]  M. Braga,et al.  Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer , 2015, Tumor Biology.

[59]  J. Round,et al.  Defining dysbiosis and its influence on host immunity and disease , 2014, Cellular microbiology.

[60]  T. Conroy,et al.  Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. , 2014, The Lancet. Oncology.

[61]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[62]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[63]  C. Bassi,et al.  Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[64]  I. Martínez,et al.  Gut microbiome composition is linked to whole grain-induced immunological improvements , 2012, The ISME Journal.

[65]  E. Van Cutsem,et al.  Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  I. Spreadbury.  Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity , 2012, Diabetes, metabolic syndrome and obesity : targets and therapy.

[67]  Ateequr Rehman,et al.  Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. , 2011, Gastroenterology.

[68]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[69]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? , 2010, Journal of the National Cancer Institute.

[70]  Weiwen Zhang,et al.  Integrating multiple 'omics' analysis for microbial biology: application and methodologies. , 2010, Microbiology.

[71]  N. Kyrpides.  Fifteen years of microbial genomics: meeting the challenges and fulfilling the dream , 2009, Nature Biotechnology.

[72]  Julian Parkhill,et al.  Microbiology in the post-genomic era , 2008, Nature Reviews Microbiology.

[73]  J. Jansson,et al.  Molecular analysis of the gut microbiota of identical twins with Crohn's disease , 2008, The ISME Journal.

[74]  H. Schrem,et al.  Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[75]  I. B. Borel Rinkes,et al.  Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. , 2018, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[76]  H. Ogata,et al.  Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. , 2018, Biochemical and biophysical research communications.

[77]  E. Nakakura,et al.  Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[78]  M. Hattori,et al.  Our second genome-human metagenome: how next-generation sequencer changes our life through microbiology. , 2013, Advances in microbial physiology.

[79]  Z. Naito,et al.  Report on Experiments and Clinical Cases ― Clinicopathological Features of 30 Autopsy Cases of Pancreatic Carcinoma , 2012 .